Dr Francesco Iorio

Wellcome Trust Sanger Institute

Position: Principal Staff Scientist - DepMap Analytics Team Leader
Personal home page: http://www.sanger.ac.uk/people/directory/iorio-francesco
Email:   Public email address:  francesco.iorio@sanger.ac.uk

PubMed journal articles - click here

Research description

Development of new algorithms and computational tools for the analysis of large-scale cancer pharmacogenomics and functional genomics datasets (from chemical and genome editing screens) for identifying molecular markers of drug response and new oncology therapeutic targets.
Design of analytical methods and software, and the management of day-by-day operations to deliver scientific milestones toward the definition of a global Cancer Dependency Map: an atlas of genetic dependencies and vulnerabilities, at an individual cancer cell resolution, which could be exploited for the development of cancer targeted and personalized therapies.

Research Programme
Methods and technologies
Computational modelling
Statistical analysis
Tumour type interests
Bone and connective tissue

Key publications

Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
Iorio F, Behan FM, Gon├žalves E, Bhosle SG, Chen E et al.
BMC genomics 2018;19;1;604
PUBMED: 30103702; DOI: 10.1186/s12864-018-4989-y

Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich.
Iorio F, Garcia-Alonso L, Brammeld JS, Martincorena I, Wille DR et al.
Scientific reports 2018;8;1;6713
PUBMED: 29713020; PMC: 5928049; DOI: 10.1038/s41598-018-25076-6

Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.
Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P et al.
Cancer research 2018;78;3;769-780
PUBMED: 29229604; DOI: 10.1158/0008-5472.CAN-17-1679

A Landscape of Pharmacogenomic Interactions in Cancer.
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP et al.
Cell 2016;166;3;740-754
PUBMED: 27397505; PMC: 4967469; DOI: 10.1016/j.cell.2016.06.017

Pharmacogenomic agreement between two cancer cell line data sets.
Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium
Nature 2015;528;7580;84-7
PUBMED: 26570998; DOI: 10.1038/nature15736

Prospective derivation of a living organoid biobank of colorectal cancer patients.
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F et al.
Cell 2015;161;4;933-45
PUBMED: 25957691; DOI: 10.1016/j.cell.2015.03.053

Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery.
Schubert M and Iorio F
Pharmacogenomics 2014;15;16;1943-6
PUBMED: 25521353; DOI: 10.2217/pgs.14.157

Discovery of drug mode of action and drug repositioning from transcriptional responses.
Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P et al.
Proceedings of the National Academy of Sciences of the United States of America 2010;107;33;14621-6
PUBMED: 20679242; PMC: 2930479; DOI: 10.1073/pnas.1000138107

A yeast synthetic network for in vivo assessment of reverse-engineering and modeling approaches.
Cantone I, Marucci L, Iorio F, Ricci MA, Belcastro V et al.
Cell 2009;137;1;172-81
PUBMED: 19327819; DOI: 10.1016/j.cell.2009.01.055